Pay in 4 interest-free payments of $7.47 Learn more
Ships within 48 hours · Estimated delivery Sep 7 - Sep 12
Mol Cell Endocrinol (2018) 465:13
This comprehensive two-day masterclass series will explore the past, present, and future of incretin-based therapies in the management of obesity, type 2 diabetes, and related comorbidities.
Obesity is a major risk factor for many chronic conditions like type 2 diabetes and cardiovascular diseases
This conception has been changing during recent years, since it has been reported that resistance to GIP can be reversed and its effectiveness restored by improving glycemic control [14]
These medications can cause low blood sugar when combined with GLP-1 drugs
US$ 27.39
US$ 29.36
US$ 22.76
US$ 24.64
US$ 25.73
